Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Common Equity (2020 - 2025)

Bioventus (BVS) has disclosed Common Equity for 6 consecutive years, with $228.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 23.08% year-over-year to $228.4 million, compared with a TTM value of $228.4 million through Dec 2025, up 23.08%, and an annual FY2025 reading of $228.4 million, up 23.08% over the prior year.
  • Common Equity was $228.4 million for Q4 2025 at Bioventus, up from $166.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $607.7 million in Q4 2021 and bottomed at $152.5 million in Q4 2021.
  • Average Common Equity over 5 years is $286.5 million, with a median of $220.7 million recorded in 2021.
  • The sharpest move saw Common Equity skyrocketed 321.51% in 2021, then plummeted 60.59% in 2023.
  • Year by year, Common Equity stood at $607.7 million in 2021, then tumbled by 32.16% to $412.2 million in 2022, then crashed by 46.36% to $221.1 million in 2023, then fell by 16.06% to $185.6 million in 2024, then rose by 23.08% to $228.4 million in 2025.
  • Business Quant data shows Common Equity for BVS at $228.4 million in Q4 2025, $166.1 million in Q3 2025, and $201.3 million in Q2 2025.